title: [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases].
abstract: BACKGROUND
  Selective serotonin reuptake inhibitors are widely used in the treatment of depressive and obsessive-compulsive disorders because of their low-frequency adverse effects. We report two cases of cutaneous adverse effects during selective serotonin reuptake inhibitors therapy.
  
  
  METHODS
  A man who complained of chronic anal idiopathic pruritus was treated with citalopram (Seropram(R)) 10 mg b.i.d. Six days after the beginning of the antidepressive treatment, he developed an extensive papular and purpuric erythema with keratinocytes necrosis and dermal leucocytoclastic vasculitis. Cutaneous lesions remained for several weeks, as the half-life of citalopram is very long (33 to 36 hours) but did not relapse. A women developed painful papular and purpuric erythema mainly located in sun-exposed sites, during therapy with paroxetine (Deroxat(R)) 20 mg b.i.d., which had been introduced one month before to treat depression. Cutaneous lesions healed spontaneously in 2 weeks after the discontinuation of paroxetine and with sun avoidance and didn't relapse.
  
  
  CONCLUSIONS
  Adverse cutaneous effects of selective serotonin reuptake inhibitors are rare but the knowledge of these reactions is important because toxic epidermal necrolysis and Stevens-Johnson syndrome had been reported during fluoxetine (Prozac(R)) and fluvoxamine (Floxyfral(R)) treatment. Different serotonin uptake blockers could be involved in the same allergic reaction, suggesting cross reactivity, although these drugs have different chemistry structures. It is advisable to substitute after an adverse effect a medication from one of the other classes of antidepressants.
authors.affiliation: Service de Dermatologie, Hôpital Sainte-Marguerite, Marseille. mrichard@mail.ap-hm.fr
authors.forename: M A
authors.initials: MA
authors.lastname: Richard
authors.forename: F
authors.initials: F
authors.lastname: Fiszenson
authors.forename: M
authors.initials: M
authors.lastname: Jreissati
authors.forename: M J
authors.initials: MJ
authors.lastname: Jean Pastor
authors.forename: J J
authors.initials: JJ
authors.lastname: Grob
mesh_terms: D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy; D015283:Citalopram / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000009:adverse effects* / Q000627:therapeutic use; D010787:Photosensitivity Disorders / Q000139:chemically induced* / Q000175:diagnosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013001:Somatoform Disorders / Q000188:drug therapy
chemical_list: D015283:Citalopram; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors